EUVIMEDEUVIMED entdecken
Open Access

Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition‐Mediated Cuproptosis for Highly Efficient Oncotherapy

Sheng-Yan Yin, Guangxia Lv, Lele Ma iD, Deyu Bu, Huiying Zheng, Jiangshen Guo, Zhen Zhang, Xiaotao Zhang iD, Ruihua Dong iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.71530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Sheng-Yan Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Qingdao Center of Technology Innovation For AIE Theranostics and Rehabilitation, School of Rehabilitation Sciences and Engine…. Hauptthemen laut MEDLINE: Cuproptosis, Lactate Dehydrogenase 5, Copper, Nanoparticles. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of China, Qingdao Natural Science Foundation, Young Taishan Scholars Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cuproptosis, heavily dependent on copper and mitochondrial tricarboxylic acid (TCA) cycle, can be exploited as a potential oncotherapy. However, the primary metabolic pathway of tumor cells is dependent on glycolysis owing to the overexpression of lactate dehydrogenase A (LDHA), which suppresses high‐efficiency cuproptosis oncotherapy. Therefore, inhibiting LDHA to remodel the metabolic pathway of tumor cells could result in sensitizing cuproptosis and, hence, provide a novel strategy to achieve efficient oncotherapy. Accordingly, we herein report a pH‐responsive, copper‐engineered nanoplatform (ZCIF@GSK) encapsulating the LDHA inhibitor (GSK). ZCIF@GSK initiates the reprogramming of cellular metabolism, thereby achieving efficient cuproptosis. Under the low pH tumor environment, ZCIF@GSK specifically releases GSK to inhibit LDHA. This, in turn, inhibits glycolysis but promotes mitochondrial TCA cycle, to sensitize cuproptosis. Meanwhile, the release kinetics of copper further causes the oligomerization of lipoylated dihydrolipoamide S‐acetyltransferase (DLAT) and the downregulation of lipoic acid synthase (LIAS), contributing to efficient cuproptosis. Overall, we propose a novel strategy for sensitizing cuproptosis through an LDHA inhibitor. Additionally, we demonstrate that the inhibition of LDHA upregulates the expression of ferredoxin (FDX1), a key regulator of cuproptosis, further promoting the sensitization of cuproptosis and, hence, a promising cuproptosis‐based oncotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CuproptosisLactate Dehydrogenase 5CopperNanoparticlesNeoplasmsL-Lactate DehydrogenaseHumansAnimalsCell Line, TumorCitric Acid CycleGlycolysisMiceMitochondria

Stichwörter der Autor:innen

cellular metabolic reprogrammingcuproptosisferredoxinlactate dehydrogenase Atumor microenvironment

Substanzen

Lactate Dehydrogenase 5CopperL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Department of Oncology, Qingdao Center of Technology Innovation For AIE Theranostics and Rehabilitation, School of Rehabilitation Sciences and Engineering, Qingdao Central Hospital, University of Health and Rehabilitati…

ORCID-Profile: Lele Ma, Xiaotao Zhang, Ruihua Dong

Förderung

  • Natural Science Foundation of China
  • Qingdao Natural Science Foundation
  • Young Taishan Scholars Program of Shandong Province
  • Shandong Provincial Natural Science Foundation
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yin, S. Y., Lv, G., Ma, L., Bu, D., Zheng, H., Guo, J., Zhang, Z., Zhang, X., & Dong, R. (2026). Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition‐Mediated Cuproptosis for Highly Efficient Oncotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71530

Vancouver

Yin SY, Lv G, Ma L, Bu D, Zheng H, Guo J, et al. Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition‐Mediated Cuproptosis for Highly Efficient Oncotherapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71530

BibTeX
@article{Yin2026,
  author = {Yin, Sheng-Yan and Lv, Guangxia and Ma, Lele and Bu, Deyu and Zheng, Huiying and Guo, Jiangshen and Zhang, Zhen and Zhang, Xiaotao and Dong, Ruihua},
  title = {Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition‐Mediated Cuproptosis for Highly Efficient Oncotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.71530}
}
Kostenlos starten →